Benzinga | Oct 29, 2020 09:25AM EDT

Piper Sandler Maintains Overweight on CRISPR Therapeutics, Lowers Price Target to $107

Piper Sandler maintains CRISPR Therapeutics (NASDAQ:CRSP) with a Overweight and lowers the price target from $128 to $107.